Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations
Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Medicare drug price negotiations to target Ozempic, Wegovy and other drugs
Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer medications and other drugs, for its second round of price talks.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.
Medicare Price Negotiations: A New Chapter for High-Cost Drugs
The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction Act. This includes Novo Nordisk's drugs like Ozempic and Wegovy. There are concerns about the policy's impact on innovation and its political implications with the incoming administration.
FiercePharma1h
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Novo Trial Shows Bigger Dose of Wegovy Helps Shed Pounds
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...